RUNX2 is overexpressed in various cancers, including breast (BC) and thyroid cancer (TC) [16, 17], where it promotes metastasis by regulating key functions such as stress resistance and phenotypic plasticity through processes like the Epithelial-to-Mesenchymal Transition (EMT) [15, 18, 19] and osteomimicry [20–26]. Here, RUNX2 is linked to breast cancer.